Spontaneous intracerebral hematomas (ICH) are the most deadly form of stroke. Treatment options include admission to a specialized stroke unit and treatment of hypertension in the acute stage. However, both of these options have exhibited limited effectiveness. The RICH biobank collects biomaterial (DNA, plasma, serum and PAXgene) from patients with spontaneous ICH at different times in the first week after the bleeding, in order to:
1) gain insight into the role of inflammation in the development of secondary brain damage;
2) be able to explore different anti-inflammatory drugs in an ex vivo model for potential effectiveness, determined by the macrophage cytokine production capacity;
3) evaluate the effect of anti-inflammatory drug treatment in a phase II trial on markers of systemic inflammation;
4) to evaluate the effect of minimally invasive neurosurgical defecation of ICH versus regular treatment in a phase III trial on markers of systemic inflammation.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Framework for standards and assessment of accessing identifiable patient data for medical scientific research28 January 2021
A Framework for standards and assessment of accessing identifiable patient data for medical scientific research has been developed in the Radboudumc.read more